Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) announced its earnings results on Friday. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.44) by $0.47, Briefing.com reports. The firm had revenue of $31.45 million for the quarter, compared to the consensus estimate of $20.35 million. Y-mAbs Therapeutics had a negative net margin […]
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) released its quarterly earnings results on Friday. The company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.44) by $0.47, Briefing.com reports. Y-mAbs Therapeutics had a negative net margin of 146.43% and a negative return on equity of 72.26%. The business had revenue of $31.45 million […]
Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 11,186 shares of the company’s stock, valued at approximately $169,000. Other hedge […]
Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) have earned an average rating of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month target price among […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) has been assigned a consensus rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price […]